Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 16/20 | 0.33 |
| ▸ | AKT2 | P31751 | 12/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2027013 | 0.88 | AKT1 (0.35) | AKT1AKT2 | |
| SCHEMBL2029992 | 0.88 | AKT1 (0.35) | AKT1AKT2 | |
| SCHEMBL2034120 | 0.83 | AKT1 (0.41) | HSD11B1CYP3A4CYP2D6CYP2C9AKT1 | |
| SCHEMBL12583548 | 0.82 | AKT1 (0.47) | HSD11B1AKT1AKT2 | |
| SCHEMBL2027037 | 0.82 | AKT1 (0.49) | AKT1AKT2 | |
| Hydrochloric Acid SCHEMBL2028795 | 0.81 | AKT1 (0.48) | CYP3A4CYP2D6CYP2C9AKT1AKT2 | |
| SCHEMBL1674617 | 0.74 | AKT1 (0.53) | AKT1AKT2 | |
| SCHEMBL1674616 | 0.74 | AKT1 (0.53) | AKT1AKT2 | |
| SCHEMBL2028778 | 0.72 | KDM4E (0.39) | — | |
| SCHEMBL1674685 | 0.72 | AKT1 (0.42) | AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160183-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20090253734-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-7576209-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080161317-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME LLC | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161317-A1 | Inhibitors of Akt activity | PIK3CD, PIK3CA, PIK3CG | HSD11B1 2742/4885CYP3A4 3185/4885CYP2D6 3357/4885 |
| US-20110160183-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3CG | HSD11B1 2742/4885CYP3A4 3185/4885CYP2D6 3357/4885 |
| US-20090253734-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3CG | HSD11B1 2742/4885CYP3A4 3185/4885CYP2D6 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.